251. Polychemotherapy with carmustine, cyclophosphamide plus adriamycin in the treatment of advanced ovarian cancer.
- Author
-
Facchini V, Gadducci A, Bogi G, Colombi L, Basile AG, Ballantini M, De Pasquale F, and Fioretti P
- Subjects
- Adenocarcinoma drug therapy, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Carcinoma drug therapy, Carmustine administration & dosage, Cisplatin therapeutic use, Cyclophosphamide administration & dosage, Cystadenocarcinoma drug therapy, Doxorubicin administration & dosage, Female, Humans, Middle Aged, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Ovarian Neoplasms drug therapy
- Abstract
The Authors describe their experience with a combination therapy with carmustine (BCNU), cyclophosphamide (CTX) plus adriamycin (ADM) in the treatment of advanced ovarian cancer. The complete remission was obtained in 33.3% of subjects, the partial remission in 37.5%. Almost all patients suffered nausea, vomiting and alopecia. Myelosuppression was acceptable. No heart damage was observed. This pharmacological association can be considered an effective medical treatment in the management of ovarian carcinomas in advanced stages.
- Published
- 1985